Myriad Genetics (MYGN) 10-Q 5 Feb 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Dec. 31, 2013	Jan. 31, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'MYGN	'
Entity Registrant Name	'MYRIAD GENETICS INC	'
Entity Central Index Key	'0000899923	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	72,974,449

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$71,599	$104,073
Marketable investment securities	281,996	268,243
Prepaid expenses	4,237	5,963
Trade accounts receivable, less allowance for doubtful accounts of $9,200 at Dec. 31, 2013 and $7,500 at Jun. 30, 2013	84,137	94,333
Deferred taxes	9,074	8,007
Other receivables	3,463	3,373
Total current assets	454,506	483,992
Equipment and leasehold improvements:	'	'
Equipment	73,570	65,903
Leasehold improvements	18,390	18,294
Gross equipment and leasehold improvements	91,960	84,197
Less accumulated depreciation	60,647	56,595
Net equipment and leasehold improvements	31,313	27,602
Long-term marketable investment securities	135,187	158,748
Long-term deferred taxes	29,983	28,632
Note receivable	23,000	21,667
Other assets	13,000	13,000
Intangibles, net	12,842	13,330
Goodwill	56,850	56,850
Total assets	756,681	803,821
Current liabilities:	'	'
Accounts payable	17,596	18,132
Accrued liabilities	45,844	44,334
Deferred revenue	3,952	2,043
Total current liabilities	67,392	64,509
Unrecognized tax benefits	13,318	10,718
Total liabilities	80,710	75,227
Stockholders' equity:	'	'
Preferred stock, $0.01 par value, authorized 5,000 shares, issued and outstanding no shares	'	'
Common stock, $0.01 par value, authorized 150,000 shares at Dec. 31, 2013 and Jun. 30, 2013, issued and outstanding 73,974 at Dec. 31, 2013 and 80,577 at Jun. 30, 2013	740	806
Additional paid-in capital	663,122	697,346
Accumulated other comprehensive income (loss)	506	-424
Retained earnings	11,603	30,866
Total stockholders' equity	675,971	728,594
Total liabilities and stockholders' equity	$756,681	$803,821

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, except Per Share data, unless otherwise specified
Allowance for doubtful accounts	$9,200	$7,500
Preferred stock, par value	$0.01	$0.01
Preferred stock, authorized	5,000	5,000
Preferred stock, issued	'	'
Preferred stock, outstanding	'	'
Common stock, par value	$0.01	$0.01
Common stock, authorized	150,000	150,000
Common stock, issued	73,974	80,577
Common stock, outstanding	73,974	80,577

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income and Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Molecular diagnostic testing	$196,158	$140,651	$389,144	$267,919
Companion diagnostic services	7,902	8,489	17,383	14,658
Total revenue	204,060	149,140	406,527	282,577
Costs and expenses:	'	'	'	'
Cost of molecular diagnostic testing	22,755	15,566	44,194	29,498
Cost of companion diagnostic services	3,376	4,318	7,418	7,713
Research and development expense	17,090	14,107	33,893	25,507
Selling, general, and administrative expense	77,840	59,563	155,119	115,691
Total costs and expenses	121,061	93,554	240,624	178,409
Operating income	82,999	55,586	165,903	104,168
Other income (expense):	'	'	'	'
Interest income	1,330	1,385	2,691	2,753
Other	-185	14	-623	-114
Total other income	1,145	1,399	2,068	2,639
Income before income taxes	84,144	56,985	167,971	106,807
Income tax provision	33,784	21,949	62,146	41,635
Net income	50,360	35,036	105,825	65,172
Earnings per share:	'	'	'	'
Basic	$0.67	$0.43	$1.37	$0.80
Diluted	$0.66	$0.42	$1.33	$0.78
Weighted average shares outstanding	'	'	'	'
Basic	75,070	81,692	77,323	81,632
Diluted	76,825	84,240	79,312	84,091
Net income	50,360	35,036	105,825	65,172
Comprehensive income:	'	'	'	'
Unrealized gain (loss) on available-for-sale securities, net of tax	253	-70	538	13
Change in foreign currency translation adjustment, net of tax	-112	-280	392	-72
Comprehensive income	$50,501	$34,686	$106,755	$65,113

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net income	$105,825	$65,172
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	4,811	4,455
Loss on disposition of assets	40	4
Share-based compensation expense	13,792	13,704
Bad debt expense	21,793	14,729
Impairment of intangible asset	'	1,490
Accreted interest on note receivable	-1,333	-1,333
Unrecognized tax benefits	2,600	130
Excess tax benefit from share-based compensation	-592	-3,623
Deferred income taxes	-1,826	5,899
Changes in operating assets and liabilities:	'	'
Prepaid expenses	1,807	501
Trade accounts receivable	-11,597	-29,851
Other receivables	-172	1,672
Accounts payable	-536	3,434
Accrued liabilities	1,510	-3,580
Deferred revenue	1,909	667
Net cash provided by operating activities	138,031	73,470
Cash flows from investing activities:	'	'
Capital expenditures for equipment and leasehold improvements	-8,098	-7,008
Purchases of marketable investment securities	-102,661	-239,264
Proceeds from maturities and sales of marketable investment securities	113,424	207,230
Net cash provided by (used in) investing activities	2,665	-39,042
Cash flows from financing activities:	'	'
Net proceeds from common stock issued under share-based compensation plans	6,362	23,903
Excess tax benefit from share-based compensation	592	3,623
Repurchase and retirement of common stock	-180,124	-79,883
Net cash used in financing activities	-173,170	-52,357
Net decrease in cash and cash equivalents	-32,474	-17,929
Cash and cash equivalents at beginning of period	104,073	86,352
Cash and cash equivalents at end of period	$71,599	$68,423

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Dec. 31, 2013
Basis of Presentation	'
	-1	Basis of Presentation
	The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2013, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2013. Operating results for the three and six months ended December 31, 2013 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Certain reclassifications have been made to prior period amounts to conform to the current period presentation.

Marketable_Investment_Securiti

Marketable Investment Securities	6 Months Ended
	Dec. 31, 2013
Marketable Investment Securities	'
	-2	Marketable Investment Securities
	The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2013 and June 30, 2013 were as follows:
	(In thousands)		Amortized		Gross		Gross			Estimated
			cost		unrealized		unrealized			fair value
					holding		holding
					gains		losses
	At December 31, 2013:
	Cash and cash equivalents:
	Cash		$	53,924	$	—	$	—		$	53,924
	Cash equivalents			17,675		—		—			17,675
	Total cash and cash equivalents			71,599		—		—			71,599
	Available-for-sale securities:
	Corporate bonds and notes			84,259		60		(1	)		84,318
	Municipal bonds			268,341		300		(99	)		268,542
	Federal agency issues			64,293		30		—			64,323
	Total available-for-sale securities			416,893		390		(100	)		417,183
	Total cash, cash equivalents and available-for-sale securities		$	488,492	$	390	$	(100	)	$	488,782
	(In thousands)		Amortized		Gross		Gross			Estimated
			cost		unrealized		unrealized			fair value
					holding		holding
					gains		losses
	At June 30, 2013:
	Cash and cash equivalents:
	Cash		$	40,412	$	—	$	—		$	40,412
	Cash equivalents			63,653		8		—			63,661
	Total cash and cash equivalents			104,065		8		—			104,073
	Available-for-sale securities:
	Corporate bonds and notes			71,626		13		(15	)		71,624
	Municipal bonds			251,513		109		(537	)		251,085
	Federal agency issues			104,293		24		(35	)		104,282
	Total available-for-sale securities			427,432		146		(587	)		426,991
	Total cash, cash equivalents and available-for-sale securities		$	531,497	$	154	$	(587	)	$	531,064
	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2013:
	(In thousands)		Amortized		Estimated
			cost		fair value
	Cash		$	53,924	$	53,924
	Cash equivalents			17,675		17,675
	Available-for-sale:
	Due within one year			281,882		281,996
	Due after one year through five years			135,011		135,187
	Due after five years			—		—
			$	488,492	$	488,782

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Dec. 31, 2013
Share-Based Compensation	'
	-3	Share-Based Compensation
	The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 5, 2013, the shareholders approved an amendment to the 2010 Plan to set the number of shares available for grant to 3,500,000. At December 31, 2013, 3,733,317 shares were available for issuance, which includes 233,317 shares carried over between December 6 and 31, 2013, from the Company’s 2003 Employee, Director and Consultant Option Plan (the “2003 Plan) and the 2010 Plan that were cancelled or expired without the issuance of shares of common stock by the Company. In addition, as of December 31, 2013, the Company may grant up to 6,999,352 additional shares under the 2010 Plan if options previously granted under 2003 Plan are cancelled or expire without the issuance of shares of common stock by the Company.
	The number of shares, terms, and vesting period of awards under the 2010 Plan are determined by the Compensation Committee of the Board of Directors for each equity award. Options under the plan granted prior to December 5, 2012 generally vest ratably over four years and expire ten years from the grant date. Options granted after December 5, 2012 generally vest ratably over four years and expire eight years from the grant date. The exercise price of options granted is equivalent to the fair market value of the stock on the grant date.
	The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2,000,000 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of December 31, 2013, approximately 144,000 shares of common stock have been issued under the 2012 Purchase Plan and approximately 1,856,000 were available for issuance.
	A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2013 is as follows:
			Number of		Weighted
			shares		average
					exercise
					price
	Options outstanding at June 30, 2013			14,434,970	$	21.75
	Options granted			3,304,553		26.48
	Less:
	Options exercised			310,866		14.23
	Options canceled or expired			354,729		24.33
	Options outstanding at December 31, 2013			17,073,928	$	22.75
	As of December 31, 2013, options to purchase 9,218,423 shares were vested and exercisable at a weighted average price of $21.39. As of December 31, 2013, there was $52,276,000 of total unrecognized share-based compensation expense related to share-based awards granted under the Company’s plans that will be recognized over a weighted-average period of 2.57 years.
	Share-based compensation expense recognized and included in the condensed consolidated statements of income was allocated as follows:
			Three months ended				Six months ended
			December 31,				December 31,
	(In thousands)		2013		2012		2013		2012
	Cost of molecular diagnostic testing		$	209	$	271	$	432	$	560
	Cost of companion diagnostic services			74		47		137		104
	Research and development expense			846		869		1,627		1,678
	Selling, general, and administrative expense			5,728		5,918		11,596		11,362
	Total share-based compensation expense		$	6,857	$	7,105	$	13,792	$	13,704

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Dec. 31, 2013
Stockholders' Equity	'
	-4	Stockholders’ Equity
	Share Repurchase Program
	In November 2013, the Company completed its fifth share repurchase program, which authorized the repurchase of up to $200 million of the Company’s common stock. In November 2013, the Company’s Board of Directors authorized a sixth share repurchase program of $300 million of the Company’s outstanding common stock. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of December 31, 2013, approximately $273.3 million remained available for repurchases under the sixth program. The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to retained earnings. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to retained earnings for the repurchases for the three and six months ended December 31, 2013 and 2012 were as follows:
			Three months ended				Six months ended
			December 31,				December 31,
	(In thousands)		2013		2012		2013		2012
	Shares purchased and retired			3,185		1,231		6,991		3,067
	Common stock and additional paid-in-capital reductions		$	25,096	$	9,372	$	55,036	$	23,122
	Charges to retained earnings		$	52,713	$	24,311	$	125,088	$	56,760

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Dec. 31, 2013
Earnings Per Share	'
	-5	Earnings Per Share
	Basic earnings per share is computed based on the weighted-average number of shares of the Company’s common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of the Company’s common stock, including the dilutive effect of common stock equivalents outstanding.
	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
			Three months ended				Six months ended
			December 31,				December 31,
	(In thousands)		2013		2012		2013		2012
	Denominator:
	Weighted-average shares outstanding used to compute basic earnings per share			75,070		81,692		77,323		81,632
	Effect of dilutive stock options			1,755		2,548		1,989		2,459
	Weighted-average shares outstanding and dilutive securities used to compute dilutive earnings per share			76,825		84,240		79,312		84,091
	Certain outstanding stock options were excluded from the computation of diluted earnings per share for the three and six months ended December 31, 2013 and 2012 because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
			Three months ended				Six months ended
			December 31,				December 31,
	(In thousands)		2013		2012		2013		2012
	Anti-dilutive options excluded from EPS computation			8,500		5,605		7,136		4,585

Segment_and_Related_Informatio

Segment and Related Information	6 Months Ended
	Dec. 31, 2013
Segment and Related Information	'
	-6	Segment and Related Information
	The Company’s business units have been aggregated into three reportable segments: (i) research, (ii) molecular diagnostics and (iii) companion diagnostics. The research segment is focused on the discovery of genes, biomarkers and proteins related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company evaluates segment performance based on results from operations before interest income and expense and other income and expense.
	Segment revenue and operating income (loss) were as follows during the periods presented:
	(In thousands)		Research			Molecular		Companion			Total
						diagnostics		diagnostics
	Three months ended December 31, 2013:
	Revenue		$	—		$	196,158	$	7,902		$	204,060
	Depreciation and amortization			482			1,467		489			2,438
	Segment operating income (loss)			(16,286	)		98,233		1,052			82,999
	Three months ended December 31, 2012:
	Revenue		$	—		$	140,651	$	8,489		$	149,140
	Depreciation and amortization			578			1,232		401			2,211
	Segment operating income (loss)			(16,334	)		72,970		(1,050	)		55,586
	Six months ended December 31, 2013:
	Revenue		$	—		$	389,144	$	17,383		$	406,527
	Depreciation and amortization			992			2,830		989			4,811
	Segment operating income (loss)			(32,967	)		195,981		2,889			165,903
	Six months ended December 31, 2012:
	Revenue		$	—		$	267,919	$	14,658		$	282,577
	Depreciation and amortization			1,210			2,424		821			4,455
	Segment operating income (loss)			(30,765	)		138,030		(3,097	)		104,168
			Three months ended					Six months ended
			December 31,					December 31,
	(In thousands)		2013			2012		2013			2012
	Total operating income for reportable segments		$	82,999		$	55,586	$	165,903		$	104,168
	Interest income			1,330			1,385		2,691			2,753
	Other			(185	)		14		(623	)		(114	)
	Income tax provision			33,784			21,949		62,146			41,635
	Net income		$	50,360		$	35,036	$	105,825		$	65,172

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2013
Fair Value Measurements	'
	-7	Fair Value Measurements
	The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
	Level  1 —		quoted prices in active markets for identical assets and liabilities.
	Level  2 —		observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
	Level  3 —		unobservable inputs.
	The substantial majority of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. The Company reviews, tests and validates this information. The following table sets forth the fair value of the financial assets that the Company re-measured on a regular basis:
	(In thousands)		Level 1		Level 2		Level 3		Total
	at December 31, 2013:
	Money market funds (a)		$	9,351	$	—	$	—	$	9,351
	Corporate bonds and notes			—		89,318		—		89,318
	Municipal bonds			—		270,554		—		270,554
	Federal agency issues			—		65,635		—		65,635
	Total		$	9,351	$	425,507	$	—	$	434,858
	(In thousands)		Level 1		Level 2		Level 3		Total
	at June 30, 2013:
	Money market funds (a)		$	12,691	$	—	$	—	$	12,691
	Corporate bonds and notes			—		71,624		—		71,624
	Municipal bonds			—		302,055		—		302,055
	Federal agency issues			—		104,282		—		104,282
	Total		$	12,691	$	477,961	$	—	$	490,652
		(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

Income_Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2013
Income Taxes	'
	-8	Income Taxes
	In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rates from quarter to quarter.
	Income tax expense for the three months ended December 31, 2013 was $33,784,000, or approximately 40% of pre-tax income, compared to $21,949,000, for the three months ended December 31, 2012, or approximately 39% of pre-tax income. Income tax expense for the six months ended December 31, 2013 was $62,146,000, or approximately 37% of pre-tax income, compared to $41,635,000, or approximately 39% of pre-tax income. Income tax expense for the three and six months ended December 31, 2013 is based on the Company’s estimated annual effective tax rate for the full fiscal year ending June 30, 2014, adjusted by discrete items recognized during the period. For the six months ended December 31, 2013, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate of 35% primarily due to the effect of state income taxes, a deduction for the write-off of stock in a wholly-owned subsidiary recently divested, as well as timing differences related to the recognition of the tax effect of equity compensation expense from incentive stock options and the deduction realized if those options are disqualified upon exercise and sale.
	The Company files U.S., U.K., France and state income tax returns in jurisdictions with various statutes of limitations. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued. The Company’s U.S. federal tax return, U.K. and France income tax returns and all other state tax returns are not currently under examination.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	6 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets	'
	-9	Goodwill and Intangible Assets
	Goodwill
	At December 31, 2013, the Company had recorded goodwill of $56,850,000 related to the acquisition of Myriad RBM, Inc. on May 31, 2011 (formerly Rules-Based Medicine, Inc.). There were no events or circumstances that indicated that impairment exists; therefore, the Company recorded no impairment of goodwill for the three and six months ended December 31, 2013.
	Intangible Assets
	Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and tradenames as well as non-amortizable intangible assets of in-process technologies and research and development. Certain of these intangible assets were recorded as part of the Company’s purchase of Rules-Based Medicine, Inc. on May 31, 2011. The following summarizes the amounts reported as intangible assets:
	(In thousands)		Gross		Accumlated			Net
			Carrying		Amortization
			Amount
	December 31, 2013:
	Purchased licenses and technologies		$	4,500	$	(2,800	)	$	1,700
	Customer relationships			4,650		(1,208	)		3,442
	Trademarks			3,000		(100	)		2,900
	Total amortizable intangible assets			12,150		(4,108	)		8,042
	In-process research and development			4,800		—			4,800
	Total non-amortizable intangible assets			4,800		—			4,800
	Total intangible assets		$	16,950	$	(4,108	)	$	12,842
	(In thousands)		Gross		Accumlated			Net
			Carrying		Amortization
			Amount
	June 30, 2013:
	Purchased licenses and technologies		$	4,500	$	(2,644	)	$	1,856
	Customer relationships			4,650		(976	)		3,674
	Trademarks			3,000		—			3,000
	Total amortizable intangible assets			12,150		(3,620	)		8,530
	In-process research and development			4,800		—			4,800
	Total non-amortizable intangible assets			4,800		—			4,800
	Total intangible assets		$	16,950	$	(3,620	)	$	13,330
	The Company recorded amortization during the respective periods for these intangible assets as follows:
			Three months ended					Six months ended
			December 31,					December 31,
	(In thousands)		2013		2012			2013		2012
	Amortization on intangible assets		$	244	$	231		$	488	$	506

Term_Loan_and_Option_Agreement

Term Loan and Option Agreement	6 Months Ended
	Dec. 31, 2013
Term Loan and Option Agreement	'
	-10	Term Loan and Option Agreement
	On September 8, 2011, the Company issued a $25,000,000 term loan to Crescendo Bioscience, Inc. (“Crescendo”) of South San Francisco, CA under a Loan and Security Agreement (“Loan Agreement”) and also secured an exclusive three-year option to acquire Crescendo pursuant to a definitive merger agreement (the “Option Agreement”). The stated interest rate on the term loan is 7%. The fair value of the Option Agreement of $8,000,000 was determined utilizing valuation models at the time of the issuance, including the market and income based approaches, which utilize various inputs including projected income, volatility, risk free rates and projected terms. The Company periodically evaluates the Option Agreement for impairment. No impairment indicators were noted at December 31, 2013.
	The residual $17,000,000 value of the term loan has been classified as a note receivable at its accreted value of $23,000,000 on the condensed consolidated balance sheet as of December 31, 2013. The Company recorded interest income related to accretion of the note receivable and the stated interest rate for the three and six months ended December 31, 2013 of $1,104,000 and $2,208,000, respectively, in the condensed consolidated statement of income. The Company is utilizing the effective interest method to accrete the discount portion of the note receivable through interest income over the three-year term of the Company’s option to acquire Crescendo under the Option Agreement. The note receivable is evaluated for collectability each reporting period. If the Company determines that the note receivable and any accrued interest is not collectible, such amount will be written off in the period that determination is made. No amounts related to the note receivable or accrued interest were written off during the three or six months ended December 31, 2013.
	On November 14, 2013, the Company received notice from Crescendo that Crescendo had achieved the minimum revenue milestone under the Option Agreement. If the Company exercises its option to acquire Crescendo, it expects to finance the purchase price out of the Company’s cash, cash equivalents and marketable investment securities available on hand.

Cost_Basis_Investment

Cost Basis Investment	6 Months Ended
	Dec. 31, 2013
Cost Basis Investment	'
	-11	Cost Basis Investment
	As of December 31, 2013, the Company had a $5,000,000 investment in RainDance Technologies, Inc. which has been recorded under the cost method as an “Other Asset” on the Company’s condensed consolidated balance sheet. There were no events or circumstances that indicated that impairment exists; therefore, the Company recorded no impairment in the investment for the three or six months ended December 31, 2013.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2013
Commitments and Contingencies	'
	-12	Commitments and Contingencies
	The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of December 31, 2013, the management of the Company believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.

Subsequent_Event

Subsequent Event	6 Months Ended
	Dec. 31, 2013
Subsequent Event	'
	-13	Subsequent Event
	On February 2, 2014, the Company amended and restated the Option Agreement with Crescendo by entering into an amended definitive agreement and plan of merger (the “Merger Agreement”) to purchase Crescendo for $270 million in cash, subject to adjustments for Crescendo’s cash, indebtedness, working capital and other amounts to be determined in accordance with the Merger Agreement. The Company plans to utilize its existing cash and marketable investment securities to pay the purchase price to acquire Crescendo. The Company currently anticipates that the merger will be completed by the end of fiscal year 2014, subject to regulatory clearance and the satisfaction of customary closing conditions and the other terms and conditions of the Merger Agreement.

Marketable_Investment_Securiti1

Marketable Investment Securities (Tables)	6 Months Ended
	Dec. 31, 2013
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	'
	The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2013 and June 30, 2013 were as follows:
	(In thousands)	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				holding		holding
				gains		losses
	At December 31, 2013:
	Cash and cash equivalents:
	Cash	$	53,924	$	—	$	—		$	53,924
	Cash equivalents		17,675		—		—			17,675
	Total cash and cash equivalents		71,599		—		—			71,599
	Available-for-sale securities:
	Corporate bonds and notes		84,259		60		(1	)		84,318
	Municipal bonds		268,341		300		(99	)		268,542
	Federal agency issues		64,293		30		—			64,323
	Total available-for-sale securities		416,893		390		(100	)		417,183
	Total cash, cash equivalents and available-for-sale securities	$	488,492	$	390	$	(100	)	$	488,782
	(In thousands)	Amortized		Gross		Gross			Estimated
		cost		unrealized		unrealized			fair value
				holding		holding
				gains		losses
	At June 30, 2013:
	Cash and cash equivalents:
	Cash	$	40,412	$	—	$	—		$	40,412
	Cash equivalents		63,653		8		—			63,661
	Total cash and cash equivalents		104,065		8		—			104,073
	Available-for-sale securities:
	Corporate bonds and notes		71,626		13		(15	)		71,624
	Municipal bonds		251,513		109		(537	)		251,085
	Federal agency issues		104,293		24		(35	)		104,282
	Total available-for-sale securities		427,432		146		(587	)		426,991
	Total cash, cash equivalents and available-for-sale securities	$	531,497	$	154	$	(587	)	$	531,064
Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale	'
	Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2013:
	(In thousands)	Amortized		Estimated
		cost		fair value
	Cash	$	53,924	$	53,924
	Cash equivalents		17,675		17,675
	Available-for-sale:
	Due within one year		281,882		281,996
	Due after one year through five years		135,011		135,187
	Due after five years		—		—
		$	488,492	$	488,782

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2013
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding	'
	A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2013 is as follows:
		Number of		Weighted
		shares		average
				exercise
				price
	Options outstanding at June 30, 2013		14,434,970	$	21.75
	Options granted		3,304,553		26.48
	Less:
	Options exercised		310,866		14.23
	Options canceled or expired		354,729		24.33
	Options outstanding at December 31, 2013		17,073,928	$	22.75
Schedule of Share-Based Compensation Recognized in Consolidated Statements of Comprehensive Income	'
	Share-based compensation expense recognized and included in the condensed consolidated statements of income was allocated as follows:
		Three months ended				Six months ended
		December 31,				December 31,
	(In thousands)	2013		2012		2013		2012
	Cost of molecular diagnostic testing	$	209	$	271	$	432	$	560
	Cost of companion diagnostic services		74		47		137		104
	Research and development expense		846		869		1,627		1,678
	Selling, general, and administrative expense		5,728		5,918		11,596		11,362
	Total share-based compensation expense	$	6,857	$	7,105	$	13,792	$	13,704

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2013
Schedule of Stock Repurchases	'
	The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to retained earnings for the repurchases for the three and six months ended December 31, 2013 and 2012 were as follows:
		Three months ended				Six months ended
		December 31,				December 31,
	(In thousands)	2013		2012		2013		2012
	Shares purchased and retired		3,185		1,231		6,991		3,067
	Common stock and additional paid-in-capital reductions	$	25,096	$	9,372	$	55,036	$	23,122
	Charges to retained earnings	$	52,713	$	24,311	$	125,088	$	56,760

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Dec. 31, 2013
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	'
	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
		Three months ended				Six months ended
		December 31,				December 31,
	(In thousands)	2013		2012		2013		2012
	Denominator:
	Weighted-average shares outstanding used to compute basic earnings per share		75,070		81,692		77,323		81,632
	Effect of dilutive stock options		1,755		2,548		1,989		2,459
	Weighted-average shares outstanding and dilutive securities used to compute dilutive earnings per share		76,825		84,240		79,312		84,091
Schedule of Anti-Dilutive Options Excluded from EPS Computation	'
	These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
		Three months ended				Six months ended
		December 31,				December 31,
	(In thousands)	2013		2012		2013		2012
	Anti-dilutive options excluded from EPS computation		8,500		5,605		7,136		4,585

Segment_and_Related_Informatio1

Segment and Related Information (Tables)	6 Months Ended
	Dec. 31, 2013
Segment Revenue and Operating Income (Loss)	'
	Segment revenue and operating income (loss) were as follows during the periods presented:
	(In thousands)	Research			Molecular		Companion			Total
					diagnostics		diagnostics
	Three months ended December 31, 2013:
	Revenue	$	—		$	196,158	$	7,902		$	204,060
	Depreciation and amortization		482			1,467		489			2,438
	Segment operating income (loss)		(16,286	)		98,233		1,052			82,999
	Three months ended December 31, 2012:
	Revenue	$	—		$	140,651	$	8,489		$	149,140
	Depreciation and amortization		578			1,232		401			2,211
	Segment operating income (loss)		(16,334	)		72,970		(1,050	)		55,586
	Six months ended December 31, 2013:
	Revenue	$	—		$	389,144	$	17,383		$	406,527
	Depreciation and amortization		992			2,830		989			4,811
	Segment operating income (loss)		(32,967	)		195,981		2,889			165,903
	Six months ended December 31, 2012:
	Revenue	$	—		$	267,919	$	14,658		$	282,577
	Depreciation and amortization		1,210			2,424		821			4,455
	Segment operating income (loss)		(30,765	)		138,030		(3,097	)		104,168
		Three months ended					Six months ended
		December 31,					December 31,
	(In thousands)	2013			2012		2013			2012
	Total operating income for reportable segments	$	82,999		$	55,586	$	165,903		$	104,168
	Interest income		1,330			1,385		2,691			2,753
	Other		(185	)		14		(623	)		(114	)
	Income tax provision		33,784			21,949		62,146			41,635
	Net income	$	50,360		$	35,036	$	105,825		$	65,172

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2013
Schedule of Fair Value of Financial Assets	'
	The following table sets forth the fair value of the financial assets that the Company re-measured on a regular basis:
	(In thousands)		Level 1		Level 2		Level 3		Total
	at December 31, 2013:
	Money market funds (a)		$	9,351	$	—	$	—	$	9,351
	Corporate bonds and notes			—		89,318		—		89,318
	Municipal bonds			—		270,554		—		270,554
	Federal agency issues			—		65,635		—		65,635
	Total		$	9,351	$	425,507	$	—	$	434,858
	(In thousands)		Level 1		Level 2		Level 3		Total
	at June 30, 2013:
	Money market funds (a)		$	12,691	$	—	$	—	$	12,691
	Corporate bonds and notes			—		71,624		—		71,624
	Municipal bonds			—		302,055		—		302,055
	Federal agency issues			—		104,282		—		104,282
	Total		$	12,691	$	477,961	$	—	$	490,652
		(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2013
Summarized Amounts Reported as Intangible Assets	'
	The following summarizes the amounts reported as intangible assets:
	(In thousands)	Gross		Accumlated			Net
		Carrying		Amortization
		Amount
	December 31, 2013:
	Purchased licenses and technologies	$	4,500	$	(2,800	)	$	1,700
	Customer relationships		4,650		(1,208	)		3,442
	Trademarks		3,000		(100	)		2,900
	Total amortizable intangible assets		12,150		(4,108	)		8,042
	In-process research and development		4,800		—			4,800
	Total non-amortizable intangible assets		4,800		—			4,800
	Total intangible assets	$	16,950	$	(4,108	)	$	12,842
	(In thousands)	Gross		Accumlated			Net
		Carrying		Amortization
		Amount
	June 30, 2013:
	Purchased licenses and technologies	$	4,500	$	(2,644	)	$	1,856
	Customer relationships		4,650		(976	)		3,674
	Trademarks		3,000		—			3,000
	Total amortizable intangible assets		12,150		(3,620	)		8,530
	In-process research and development		4,800		—			4,800
	Total non-amortizable intangible assets		4,800		—			4,800
	Total intangible assets	$	16,950	$	(3,620	)	$	13,330
Amortization for Intangible Assets	'
	The Company recorded amortization during the respective periods for these intangible assets as follows:
		Three months ended					Six months ended
		December 31,					December 31,
	(In thousands)	2013		2012			2013		2012
	Amortization on intangible assets	$	244	$	231		$	488	$	506

Schedule_of_Fair_Value_for_Ava

Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Cash	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	$53,924	$40,412
Estimated fair value	53,924	40,412
Cash Equivalents	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	17,675	63,653
Gross unrealized holding gains	'	8
Estimated fair value	17,675	63,661
Total Cash And Cash Equivalents	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	71,599	104,065
Gross unrealized holding gains	'	8
Estimated fair value	71,599	104,073
Corporate Bonds And Notes	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	84,259	71,626
Gross unrealized holding gains	60	13
Gross unrealized holding losses	-1	-15
Estimated fair value	84,318	71,624
Municipal Bonds	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	268,341	251,513
Gross unrealized holding gains	300	109
Gross unrealized holding losses	-99	-537
Estimated fair value	268,542	251,085
Federal Agency Issues	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	64,293	104,293
Gross unrealized holding gains	30	24
Gross unrealized holding losses	'	-35
Estimated fair value	64,323	104,282
Total Available For Sale	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	416,893	427,432
Gross unrealized holding gains	390	146
Gross unrealized holding losses	-100	-587
Estimated fair value	417,183	426,991
Total Cash, Cash Equivalents & Available-For-Sale	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	488,492	531,497
Gross unrealized holding gains	390	154
Gross unrealized holding losses	-100	-587
Estimated fair value	$488,782	$531,064

Schedule_of_Maturities_of_Debt

Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale (Detail) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Net Investment Income [Line Items]	'	'
Due within one year, Amortized cost	$281,882	'
Due after one year through five years, Amortized cost	135,011	'
Due after five years, Amortized cost	'	'
Total	488,492	'
Due within one year, Estimated fair value	281,996	'
Due after one year through five years, Estimated fair value	135,187	'
Due after five years, Estimated fair value	'	'
Total	488,782	'
Cash	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	53,924	40,412
Estimated fair value	53,924	40,412
Cash Equivalents	'	'
Net Investment Income [Line Items]	'	'
Amortized cost	17,675	63,653
Estimated fair value	$17,675	$63,661

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	6 Months Ended					6 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 05, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
		Options granted after December 5, 2012	Options granted prior to December 5, 2012	The 2010 Plan	The 2010 Plan	The 2010 Plan	2012 Purchase Plan	2012 Purchase Plan
						Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Number of shares approved	'	'	'	'	3,500,000	'	1,856,000	2,000,000
Shares reserved for issuance exercise of options	'	'	'	3,733,317	'	'	'	'
Number of shares cancelled or expired without issuance	354,729	'	'	233,317	'	'	'	'
Shares available for future grant	'	'	'	'	'	6,999,352	'	'
Service period of option vested, years	'4 years	'	'	'	'	'	'	'
Options expire from date of grant, years	'	'8 years	'10 years	'	'	'	'	'
Shares issued under the Plan	'	'	'	'	'	'	144,000	'
Options to purchase shares vested and exercisable, shares	9,218,423	'	'	'	'	'	'	'
Exercisable weighted average price of options	$21.39	'	'	'	'	'	'	'
Total unrecognized share-based compensation cost related to share-based awards granted	$52,276,000	'	'	'	'	'	'	'
Total unrecognized share-based compensation cost, weighted-average period, years	'2 years 6 months 26 days	'	'	'	'	'	'	'

Schedule_of_ShareBased_Compens

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) (USD $)	6 Months Ended
	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options outstanding at beginning of year, Number of shares	14,434,970
Options granted, Number of shares	3,304,553
Options exercised, Number of shares	310,866
Options canceled or expired, Number of shares	354,729
Options outstanding at end of year, Number of shares	17,073,928
Options outstanding at beginning of year, Weighted average exercise price	$21.75
Options granted, Weighted average exercise price	$26.48
Options exercised, Weighted average exercise price	$14.23
Options canceled or expired, Weighted average exercise price	$24.33
Options outstanding at end of year, Weighted average exercise price	$22.75

Schedule_of_ShareBased_Compens1

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Comprehensive Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total share-based compensation expense	$6,857	$7,105	$13,792	$13,704
Cost Of Molecular Diagnostic Testing	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total share-based compensation expense	209	271	432	560
Cost Of Companion Diagnostic Services	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total share-based compensation expense	74	47	137	104
Research And Development Expense	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total share-based compensation expense	846	869	1,627	1,678
Selling, General, and Administrative Expenses	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total share-based compensation expense	$5,728	$5,918	$11,596	$11,362

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Nov. 30, 2013
Fifth Share Repurchase Program	'	'
Stockholders Equity Note [Line Items]	'	'
Share repurchase program, authorized amount	'	$200
Sixth Share Repurchase Program	'	'
Stockholders Equity Note [Line Items]	'	'
Share repurchase program, authorized amount	'	300
Share repurchase program, remaining authorized repurchase amount	$273.30	'

Schedule_of_Stock_Repurchases_

Schedule of Stock Repurchases (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Stockholders Equity [Line Items]	'	'	'	'
Shares purchased and retired	3,185	1,231	6,991	3,067
Common stock and additional paid-in-capital reductions	$25,096	$9,372	$55,036	$23,122
Charges to retained earnings	$52,713	$24,311	$125,088	$56,760

Reconciliation_of_Denominators

Reconciliation of Denominators of Basic and Diluted Earnings Per Share (Detail)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]	'	'	'	'
Weighted-average shares outstanding used to compute basic earnings per share	75,070	81,692	77,323	81,632
Effect of dilutive stock options	1,755	2,548	1,989	2,459
Weighted-average shares outstanding and dilutive securities used to compute dilutive earnings per share	76,825	84,240	79,312	84,091

Schedule_Of_AntiDilutive_Optio

Schedule Of Anti-Dilutive Options Excluded From EPS Computation (Detail)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive options excluded from EPS computation	8,500	5,605	7,136	4,585

Segment_and_Related_Informatio2

Segment and Related Information - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2013
	Segment
Segment Reporting Information [Line Items]	'
Number of reportable segment	3

Segment_Performance_Based_on_I

Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	$204,060	$149,140	$406,527	$282,577
Depreciation and amortization	2,438	2,211	4,811	4,455
Segment operating income (loss)	82,999	55,586	165,903	104,168
Research	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Depreciation and amortization	482	578	992	1,210
Segment operating income (loss)	-16,286	-16,334	-32,967	-30,765
Molecular Diagnostics	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	196,158	140,651	389,144	267,919
Depreciation and amortization	1,467	1,232	2,830	2,424
Segment operating income (loss)	98,233	72,970	195,981	138,030
Companion Diagnostics	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	7,902	8,489	17,383	14,658
Depreciation and amortization	489	401	989	821
Segment operating income (loss)	$1,052	($1,050)	$2,889	($3,097)

Schedule_of_Total_Operating_In

Schedule of Total Operating Income for Continuing Reportable Segments (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Total operating income for reportable segments	$82,999	$55,586	$165,903	$104,168
Interest income	1,330	1,385	2,691	2,753
Other	-185	14	-623	-114
Income tax provision	33,784	21,949	62,146	41,635
Net income	$50,360	$35,036	$105,825	$65,172

Schedule_of_Fair_Value_of_Fina

Schedule of Fair Value of Financial Assets (Detail) (USD $)	Dec. 31, 2013		Jun. 30, 2013
In Thousands, unless otherwise specified
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	$434,858		$490,652
Money Market Funds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	9,351	[1]	12,691	[1]
Corporate Bonds And Notes	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	89,318		71,624
Municipal Bonds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	270,554		302,055
Federal Agency Issues	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	65,635		104,282
Level 1	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	9,351		12,691
Level 1 | Money Market Funds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	9,351	[1]	12,691	[1]
Level 2	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	425,507		477,961
Level 2 | Corporate Bonds And Notes	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	89,318		71,624
Level 2 | Municipal Bonds	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	270,554		302,055
Level 2 | Federal Agency Issues	'		'
Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]	'		'
Total fair value of financial assets	$65,635		$104,282
[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'	'	'
Income tax expense	$33,784	$21,949	$62,146	$41,635
Approximate rate on pre-tax income	40.00%	39.00%	37.00%	39.00%
U.S. federal statutory rate	35.00%	'	35.00%	'

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2013
			Rules-Based Medicine, Inc	Rules-Based Medicine, Inc
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Goodwill Acquired	$56,850,000	$56,850,000	$56,850,000	$56,850,000
Impairment of goodwill	'	'	$0	$0

Recovered_Sheet1

Goodwill And Other Intangible Assets (Detail) (USD $)	Dec. 31, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, total intangible assets	$16,950	$16,950
Gross Carrying Amount, amortizable intangible assets	12,150	12,150
Accumulated Amortization	-4,108	-3,620
Net, total intangible assets	12,842	13,330
Net, amortizable intangible assets	8,042	8,530
Gross Carrying Amount, non-amortizable intangible assets	4,800	4,800
Net, non-amortizable intangible assets	4,800	4,800
In-Process Research And Development	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, non-amortizable intangible assets	4,800	4,800
Net, non-amortizable intangible assets	4,800	4,800
Purchased Licenses And Technologies	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, amortizable intangible assets	4,500	4,500
Accumulated Amortization	-2,800	-2,644
Net, amortizable intangible assets	1,700	1,856
Customer Relationships	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, amortizable intangible assets	4,650	4,650
Accumulated Amortization	-1,208	-976
Net, amortizable intangible assets	3,442	3,674
Trademarks	'	'
Acquired Finite And Infinite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount, amortizable intangible assets	3,000	3,000
Accumulated Amortization	-100	'
Net, amortizable intangible assets	$2,900	$3,000

Amortization_on_Intangible_Ass

Amortization on Intangible Assets (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization on intangible assets	$244	$231	$488	$506

Term_Loan_and_Option_Agreement1

Term Loan and Option Agreement - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 08, 2011	Dec. 31, 2013	Dec. 31, 2013	Jun. 30, 2013
	Y
Debt Instrument [Line Items]	'	'	'	'
Loan Agreement, principal amount	$25,000,000	'	'	'
Interest rate per annum	'	'	7.00%	'
Fair value of Option Agreement	'	8,000,000	8,000,000	'
Effective period of option, in years	3	'	'	'
Residual value of loan agreement	'	17,000,000	17,000,000	'
Accreted value of loan agreement	'	23,000,000	23,000,000	21,667,000
Interest income related to accretion of the note receivable and the stated interest rate	'	$1,104,000	$2,208,000	'

Cost_Basis_Investment_Addition

Cost Basis Investment - Additional Information (Detail) (USD $)	Dec. 31, 2013
Schedule of Cost-method Investments [Line Items]	'
Investment accounted under cost method	$5,000,000

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event, Option Agreement, Crescendo, USD $)	0 Months Ended
In Millions, unless otherwise specified	Feb. 02, 2014
Subsequent Event | Option Agreement | Crescendo	'
Subsequent Event [Line Items]	'
Cash paid for business acquisition	$270